Sufentanil

REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.

unknown title 2011

Business -- developing ARX-01, the Sufentanil NanoTab PCA System, for the management of acute post-operative pain in adult patients during hospitalization

unknown title 2011

AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, which is in preparation for Phase 3 clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps.

unknown title 2011

ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.

The Earth Times Online Newspaper 2010

ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.

The Earth Times Online Newspaper 2010

POSIDUR (TM), ELADUR (TM), and TRANSDUR (TM) - Sufentanil.

unknown title 2009

Sufentanil is a high therapeutic index opioid approved for intravenous and epidural administration.

unknown title 2009

The handheld component of ARX-01 allows for convenient patient self-administration of Sufentanil NanoTabs sublingually for oral transmucosal absorption.

unknown title 2009

POSIDUR (TM), ELADUR (TM), and TRANSDUR (TM) - Sufentanil.

unknown title 2009

POSIDUR (TM), ELADUR (TM), and TRANSDUR (TM) - Sufentanil.

unknown title 2009